NASDAQ:ABIO

ARCA biopharma Stock Dividends

NASDAQ Stock Exchange > Healthcare > Biotechnology

Open Broker Account

$2.40

+0 (+0%)

At Close: Oct 03, 2024

ARCA biopharma Stock Dividends Overview

ABIO pays dividends . Last paid amount was $1.59 at Aug 29, 2024. As of today, dividend yield (TTM) is 9.10%.

Dividend Yield Range

The Dividend Yield Range is the range of values in which a stock’s dividend yield has fluctuated within a specified period, often a year. It represents the variation between the highest and lowest dividend yields observed during that time frame.

AI Analysis of ABIO

New!

Dividend Analysis

Key Stats

Dividend Yield (TTM)	9.10%
Frequency
1Y Growth	0%
Payout Ratio	0
Amount Per Share	$1.59
ARCA biopharma has not yet announced its next dividend date. Last payment date was: Aug 29, 2024.

ABIO Dividend Payout History

To ensure a understanding of ABIO's dividend performance, consider examining the historical payout ratios and how they align with the company's earnings. Fluctuations in payout amounts may reflect changes in the company's dividend policy or earnings stability.

#	Declaration Date	Ex-Date	Pay Date	Amount	Yield
1	Aug 29, 2024	Aug 29, 2024	Aug 29, 2024	$1.59	5.30%
2	Aug 26, 2024	Aug 26, 2024	Aug 28, 2024	$1.59	3.80%

Dividend Sustainability

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Sustainability score

Low (50.00%)

Growth potential

No dividend expected

ABIO Dividend Calculator

Dividend Calculator is designed to forecast the potential returns from ABIO dividends based on your individual investment size or the number of shares you own. Simply enter your total investment amount to see the cumulative dividend payment you could receive over a specified period.
Read how to invest in ABIO stock here.

Comparing ABIO to Sector and Country

ABIO pays a solid dividend yield of 9.10%, which is higher than the average of the bottom 25% of dividend payers in the US market (0.474%). ABIO’s dividend yield is higher than the average of the top 25% of dividend payers in the Healthcare sector in the US market (8.90%).

ABIO Stock Competitors

Symbol	Company Name	Market Cap	Amount Per Share	Dividend Yield (TTM)	Payout Ratio (TTM)
ABIO	ARCA biopharma	34.817M	$1.59	9.10%	-

FAQ

What factors can affect the amount of ABIO's dividend payments?

The amount of ABIO's dividends can fluctuate based on several factors, including the company's financial performance, earnings, cash flow, capital requirements, and overall market conditions. Changes in ABIO sector's trends, interest rate shifts, and the company's operational adjustments can also influence dividend decisions.

Can dividends from ABIO stock be automatically reinvested?

If ABIO offers a Dividend Reinvestment Plan (DRIP), shareholders may have the option to automatically reinvest dividends to purchase additional shares. Please check with your brokerage for the availability and details of such a plan. Here's an easy guide on how to buy ABIO stock.

How often does ABIO pay dividend?

ARCA biopharma (ABIO) pays dividends . The most recent payout was on Aug 29, 2024.

How much does ABIO pays per share?

The last recorder (Aug 29, 2024) dividend per share was $1.59.

What is ABIO dividend growth rate?

Over the last year, ARCA biopharma has witnessed growth rate of 0% . Looking back over the past 3 years, this growth rate has been 0%. Furthermore, examining the past 5 years, ARCA biopharma has maintained an average Dividends Per Share Growth Rate of 0%.

ABOUT ARCA BIOPHARMA

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase...

Read Full Profile Here